In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans (Q43515268)

24 November 2017

title

In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans (English)

1 reference

24 November 2017

main subject

Mycobacterium ulcerans

0 references

1 reference

Dhople AM

1

1 reference

24 November 2017

publication date

1 January 2001

1 reference

International Journal of Antimicrobial Agents

24 November 2017

published in

1 reference

24 November 2017

volume

17

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

57-61

1 reference

A new mycobacterial infection in man.

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Evaluation of the BACTEC radiometric method for detection of 1% resistant populations of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Mycobacterium ulcerans--a mini-review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900306-X

7 January 2021

10.1016/S0924-8579(00)00306-X

Identifiers

DOI

1 reference

24 November 2017

1 reference